Brought to you by 
Proximagen partners CNS program with Boehringer
Feb 2008
Executive Summary
Boehringer Ingelheim and public UK biotech Proximagen Neuroscience PLC have agreed to research and develop one of the latter's CNS programs.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com